Investing IdeasBrowse All StocksMarkets
Have your own idea? Try our Stock Screener
Header cover image

U.S. Healthtech Industry Analysis

UpdatedAug 29, 2026
DataAggregated Company Financials
Companies70
  • 7D7.8%
  • 3M45.6%
  • 1Y-12.4%
  • YTD11.2%

The Healthtech industry is up 7.8% in the last week, with Veeva Systems up 12%. In contrast, the industry has lost 12% in the last 12 months. As for the next few years, earnings are expected to grow by 20% per annum.

Industry Valuation and Performance

Has the U.S. Healthtech Industry valuation changed over the past few years?

DateMarket CapRevenueEarningsPEAbsolute PEPS
Sat, 29 Aug 2026US$69.5bUS$13.8b-US$248,211,114.0038.9x-280x5x
Mon, 27 Jul 2026US$49.8bUS$13.4b-US$390,407,179.0033.2x-127.6x3.7x
Wed, 24 Jun 2026US$43.8bUS$14.4b-US$757,222,179.0027.8x-57.8x3.1x
Fri, 22 May 2026US$44.9bUS$13.6b-US$505,371,035.0028.5x-88.9x3.3x
Sun, 19 Apr 2026US$47.8bUS$13.6b-US$417,856,415.0031.8x-114.3x3.5x
Tue, 17 Mar 2026US$48.5bUS$13.5b-US$388,664,318.0032.4x-124.7x3.6x
Thu, 12 Feb 2026US$51.0bUS$13.6b-US$115,740,340.0039.9x-440.4x3.7x
Sat, 10 Jan 2026US$67.7bUS$13.6b-US$102,102,340.0054.4x-663.4x5x
Mon, 08 Dec 2025US$68.3bUS$13.6b-US$119,482,271.0055.4x-571.6x5x
Wed, 05 Nov 2025US$80.0bUS$13.1b-US$205,571,903.0059.4x-389.1x6.1x
Fri, 03 Oct 2025US$81.8bUS$13.1b-US$211,110,296.0060.9x-387.4x6.2x
Sun, 31 Aug 2025US$76.9bUS$13.2b-US$285,313,296.0054.5x-269.4x5.8x
Tue, 29 Jul 2025US$79.8bUS$13.3b-US$1,473,336,447.0061.2x-54.1x6x
Thu, 26 Jun 2025US$77.9bUS$13.2b-US$1,382,394,447.0054.6x-56.4x5.9x
Sat, 24 May 2025US$67.8bUS$13.1b-US$1,464,882,390.0051.8x-46.3x5.2x
Mon, 21 Apr 2025US$65.4bUS$13.2b-US$1,417,865,959.0049.6x-46.1x5x
Wed, 19 Mar 2025US$70.5bUS$13.2b-US$1,408,039,877.0057.1x-50.1x5.4x
Fri, 14 Feb 2025US$75.6bUS$12.9b-US$1,604,881,514.0064.4x-47.1x5.9x
Sun, 12 Jan 2025US$66.5bUS$12.9b-US$1,638,075,735.0054.5x-40.6x5.2x
Tue, 10 Dec 2024US$71.8bUS$12.9b-US$1,662,130,390.0058.8x-43.2x5.6x
Thu, 07 Nov 2024US$63.0bUS$12.6b-US$1,843,119,656.0049x-34.2x5x
Sat, 05 Oct 2024US$63.3bUS$14.0b-US$3,264,827,208.0052.9x-19.4x4.5x
Mon, 02 Sep 2024US$65.9bUS$14.0b-US$3,320,322,604.0057.6x-19.8x4.7x
Wed, 31 Jul 2024US$60.4bUS$13.7b-US$1,841,437,711.0053x-32.8x4.4x
Fri, 28 Jun 2024US$57.1bUS$13.7b-US$1,909,009,047.0047.5x-29.9x4.2x
Sun, 26 May 2024US$57.6bUS$12.7b-US$1,960,913,856.0046.2x-29.4x4.5x
Tue, 23 Apr 2024US$56.8bUS$12.7b-US$1,624,501,542.0048.5x-35x4.5x
Thu, 21 Mar 2024US$64.6bUS$14.3b-US$1,475,736,316.0050.4x-43.8x4.5x
Sat, 17 Feb 2024US$66.1bUS$13.8b-US$5,663,248,794.0062.3x-11.7x4.8x
Mon, 15 Jan 2024US$74.0bUS$18.3b-US$5,780,492,665.0059.3x-12.8x4x
Wed, 13 Dec 2023US$66.1bUS$18.3b-US$5,772,419,665.0051.3x-11.4x3.6x
Fri, 10 Nov 2023US$62.3bUS$18.2b-US$5,891,219,304.0046.4x-10.6x3.4x
Sun, 08 Oct 2023US$70.8bUS$18.0b-US$5,559,240,965.0053.6x-12.7x3.9x
Tue, 05 Sep 2023US$75.4bUS$18.0b-US$5,525,678,389.0051.2x-13.6x4.2x
Price to Earnings Ratio

-13.6x


Total Market Cap: US$75.4bTotal Earnings: -US$5,525,678,389.00Total Revenue: US$18.0bTotal Market Cap vs Earnings and Revenue0%0%0%
U.S. Healthtech Industry Price to Earnings3Y Average -139.1x202420252026
Current Industry PE
  • Investors are relatively neutral on the American Healthcare Services industry at the moment, indicating that they anticipate long term growth rates to remain steady.
  • The industry is trading close to its 3-year average PS ratio of 4.6x.
Past Earnings Growth
  • The earnings for companies in the Healthcare Services industry have improved over the last three years.
  • Meanwhile revenues for these companies have declined 8.5% per year.
  • This means that less sales are being generated overall, but since the cost of doing business is lower, losses have been shrinking.

Industry Trends

Which industries have driven the changes within the U.S. Healthcare industry?

US Market0.25%
Healthcare-2.16%
Healthtech7.78%
Healthtech7.78%
Industry PEThere are no additional sub-industries under this industry.
Forecasted GrowthThere are no additional sub-industries under this industry.

Top Stock Gainers and Losers

Which companies have driven the market over the last 7 days?

CompanyLast Price7D1YValuation
VEEV Veeva SystemsUS$276.6911.6%
+US$4.5b		2.8%PE44.1x
DOCS DoximityUS$26.735.5%
+US$249.5m		-60.7%PE28.5x
WAY Waystar HoldingUS$26.244.9%
+US$235.9m		-30.7%PE37.3x
CTEV ClaritevUS$39.395.7%
+US$35.9m		-42.8%PS0.7x
GDRX GoodRx HoldingsUS$3.532.3%
+US$27.3m		-18.9%PE74.1x

Latest News

HTFL
US$47.78
HeartFlow
7D
-4.0%
1Y
51.7%
SOPH
US$8.14
SOPHiA GENETICS
7D
-5.9%
1Y
135.3%
VEEV
US$276.69
Veeva Systems
7D
11.6%
1Y
2.8%
WAY
US$26.24
Waystar Holding
7D
4.9%
1Y
-30.7%
CTEV
US$39.39
Claritev
7D
5.7%
1Y
-42.8%
Narrative Update • Aug 27

CTEV: Q2 Beat And Raised FY26 Outlook Will Support Future Expansion

Analysts have raised Claritev's fair value estimate from $61.00 to about $72.10, citing higher modeled revenue growth, slightly stronger profit margins, and updated P/E assumptions following recent price target increases at several firms after Q2 results and refreshed outlooks. Analyst Commentary Recent research updates on Claritev show a cluster of higher price targets and generally constructive commentary, especially around the latest Q2 results, bookings trends, and medium term outlook.
SCNX
US$0.39
Scienture Holdings
7D
-12.4%
1Y
-59.6%
TDOC
US$6.50
Teladoc Health
7D
1.7%
1Y
-15.9%
DOCS
US$26.73
Doximity
7D
5.5%
1Y
-60.7%
Narrative Update • Aug 22

DOCS: AI Budget Share And Q1 AI Traction Will Drive Bullish Outlook

Analysts have lifted their Doximity price target from about $28.00 to roughly $29.78. This reflects updated models after Q1 results, differing views on AI monetization, and mixed opinions on how far current AI traction and pharma budget share can support growth amid rising competition and margin pressures.
LFMD
US$3.14
LifeMD
7D
-5.1%
1Y
-49.3%
Narrative Update • Aug 22

LFMD: GLP-1 Virtual Care And Pharmacy Expansion Will Support 2026 Outlook

The analyst price target for LifeMD has been cut, with our fair value estimate moving from $9.88 to $8.13 as analysts incorporate lower revenue growth and profit margin assumptions, along with a higher future P/E multiple following recent research updates. Analyst Commentary Recent Street research on LifeMD points to a more cautious stance on valuation, even as some analysts still see long term growth drivers in the business.
GDRX
US$3.53
GoodRx Holdings
7D
2.3%
1Y
-18.9%
Narrative Update • Aug 21

GDRX: Pharma Direct GLP-1 Momentum And New Offerings Will Drive Future Upside

GoodRx Holdings' analyst price target has increased, moving from about $3.18 to roughly $4.03. Analysts point to updated models following Q2 results, including stronger GLP-1 momentum in Pharma Direct and revised views on sector peers.
CERT
US$8.35
Certara
7D
-0.9%
1Y
-23.0%
Narrative Update • Aug 20

CERT: Execution Risks And Leadership Turnover Will Constrain Future Returns

Certara's narrative fair value has been revised from $6.00 to $7.00 as analysts recalibrate models in response to mixed price target moves and updated views on profitability, growth trajectory, and peer valuation benchmarks. Analyst Commentary Recent research on Certara reflects a mixed but generally cautious tone.
DRIO
US$6.77
DarioHealth
7D
-9.6%
1Y
-28.8%
ONMD
US$0.58
OneMedNet
7D
-3.3%
1Y
-32.6%
EVH
US$4.60
Evolent Health
7D
-3.0%
1Y
-52.3%
Seeking Alpha • Aug 13

Evolent Health Q2 Earnings Review: Debt Is Distressing, But Business Is Booming

Summary Evolent Health, Inc. is awarded a contrarian Buy rating despite extreme indebtedness and recent net losses. EVH trades at a deeply distressed valuation (~0.2x forward sales) due to ~$967m long-term debt and persistent GAAP losses. Management projects >25% revenue growth and adjusted EBITDA ≥$150m in 2027, aiming to improve leverage and capital structure. Industry recovery and strong specialty care revenue growth support the thesis, but EVH remains a high-risk, high-reward turnaround. Read the full article on Seeking Alpha
DH
US$0.80
Definitive Healthcare
7D
12.4%
1Y
-80.1%
Narrative Update • Aug 12

DH: Higher Future P/E And Product Updates Will Support Upside Potential

Analysts have cut their price target on Definitive Healthcare to $1.70 from $2.20. They point to a lower assumed fair value, a slightly higher discount rate, a smaller expected revenue decline, a much lower projected profit margin, and a materially higher future P/E multiple in their updated models.
HSTM
US$29.38
HealthStream
7D
1.8%
1Y
4.6%